A phase II study of Pemetrexed combination with Bevacizumab in the first-line treatment of elderly patients with advanced Non-squamous Non-small cell lung cancer
- Conditions
- elderly patients with stage IIIB/IV non-small cell lung cancer except for squamous cell carcinoma
- Registration Number
- JPRN-UMIN000009129
- Lead Sponsor
- Yamaguchi Thoracic Oncology Group (YTOG)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 40
Not provided
1) transfusion or G-CSF within 2weeks prior to enrollment 2) history of severe drug allergy 3) history of active double cancer within 5 years 4) history of active severe infections 5) severe cardiac disease 6) history of thromboembolism or severe pulmonary disease 7) history of GI bleeding, ileus, GI ulceration 8) history of hemoptysis (more than 2.5mL) 9) massive pleural or pericardial effusion, ascites 10) active brain metastases 11) history of mental disorder, central nervous system damage, cerebrovascular disease 12) Uncontrollable hypertension or diabetes mellitus 13)Uncontrollable diarrhea 14)Wound of unrecovery 15)bleeding diathesis or receiving anticoagulant drug(except Aspirin under 324mg/day) 16)Evaluated to be ineligible by a physician for other reasons
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method response rate
- Secondary Outcome Measures
Name Time Method disease control rate, progression free survival, overall survival, safety, evaluavte effectiveness by tumor maker(CYFRA)